Table 4 Clinical outcomes following initiation of infliximab
From: Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Organ/manifestation for which infliximab was initiated | Number of patients | Treatment success % (95% C.I) |
|---|---|---|
Lung | 14 | 78.6% (49.2–95.3) |
Cutaneous | 12 | 91.7% (61.5–99.8) |
Upper airway | 7 | 71.5% (29.0–96.3) |
CNS | 6 | 100% (54.1–100) |
Peripheral lymph node | 1 | 100% (2.5–100) |
Gastrointestinal | 1 | 100% (2.5–100) |
Uveitis | 1 | 100% (2.5–100) |
Arthritis | 1 | 0% (0.0–97.5) |
Total | 43 | 83.7% (69.3–93.2) |